AstraZeneca and Alexion Pharmaceuticals have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Alexion shareholders will receive USD 60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca’s reference average ADR price of USD 54.14, this implies total consideration to Alexion shareholders of USD 39bn or USD 175 per share.
“This implies total consideration to Alexion shareholders of USD 39 billion or USD 175 per share.”
“Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology. We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients,” says Pascal Soriot, Chief Executive Officer, AstraZeneca.
The boards of directors of both companies have unanimously approved the acquisition. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021, and upon completion, Alexion shareholders will own c.15% of the combined company.
Photo: AstraZeneca R&D
